natgillin/translations-raw huggingface dataset:
This is a summary of the European public assessment report (EPAR) for Forxiga.
See on ravimi Forxiga Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Gilenya.
See on ravimi Gilenya Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Grastofil.
See on ravimi Grastofil Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for HBVaxPro.
Käesolev dokument on vaktsiini HBVaxPro Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Hizentra.
See on ravimi Hizentra Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Humira.
See on ravimi Humira Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Iclusig.
See on ravimi Iclusig Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Imatinib Actavis.
See on ravimi Imatinib Actavis Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Imbruvica.
See on ravimi Imbruvica Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Imnovid.
See on ravimi Imnovid Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Imvanex.
See on vaktsiini Imvanex Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Incruse.
See on ravimi Incruse Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Inflacam.
See on ravimi Inflacam Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Inovelon.
See on ravimi Inovelon Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Instanyl.
See on ravimi Instanyl Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Ivabradine Anpharm.
See on ravimi Ivabradine Anpharm Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Jevtana.
Käesolev dokument on ravimi Jevtana Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Jinarc.
See on ravimi Jinarc Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Kalydeco.
See on ravimi Kalydeco Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Keytruda.
See on ravimi Keytruda Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Kineret.
See on ravimi Kineret Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Kiovig.
See on ravimi Kiovig Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Kyprolis.
See on ravimi Kyprolis Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Laventair.
See on ravimi Laventair Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Leflunomide Winthrop.
See on ravimi Leflunomide Winthrop Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Lenvima.
See on ravimi Lenvima Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Lonquex.
See on ravimi Lonquex Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Lonsurf.
See on ravimi Lonsurf Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Lucentis.
See on ravimi Lucentis Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Lumark.
See on ravimi Lumark Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Lynparza.
See on ravimi Lynparza Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for MabThera.
See on ravimi MabThera Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Mekinist.
See on ravimi Mekinist Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Metacam.
See on ravimi Metacam Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Neulasta.
Käesolev dokument on ravimi Neulasta Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for NeuroBloc.
Käesolev dokument on ravimi NeuroBloc Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Nimenrix.
See on vaktsiini Nimenrix Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Nordimet.
See on ravimi Nordimet Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for NovoEight.
See on ravimi NovoEight Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for NovoSeven.
See on ravimi NovoSeven Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Nucala.
See on ravimi Nucala Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Oncaspar.
See on ravimi Oncaspar Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Onivyde.
See on ravimi Onivyde Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Opdivo.
See on ravimi Opdivo Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Oprymea.
See on ravimi Oprymea Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Opsumit.
See on ravimi Opsumit Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Optaflu.
Optaflu influenzavakcina (sejttenyészetben előállított, inaktivált, felületi antigén)
This is a summary of the European public assessment report (EPAR) for Orkambi.
See on ravimi Orkambi Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Pandemic influenza vaccine H5N1 MedImmune.
See on Pandemic influenza vaccine H5N1 MedImmune Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Perjeta.
See on ravimi Perjeta Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Pioglitazone Accord.
Käesolev dokument on ravimi Pioglitazone Accord Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Pioglitazone Actavis.
See on ravimi Pioglitazone Actavis Group Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Plegridy.
See on ravimi Plegridy Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Pradaxa.
See on ravimi Pradaxa Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Praluent.
See on ravimi Praluent Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Privigen.
See on ravimi Privigen Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Raplixa.
See on ravimi Raplixa Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Rasilez HCT.
See on ravimi Rasilez HCT Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Ravicti.
See on ravimi Ravicti Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Relvar Ellipta.
See on ravimi Relvar Ellipta Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Remicade.
See on ravimi Remicade Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Remsima.
See on ravimi Remsima Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Repatha.
See on ravimi Repatha Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Revinty Ellipta.
See on ravimi Revinty Ellipta Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Revlimid.
See on ravimi Revlimid Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Seebri Breezhaler.
See on ravimi Seebri Breezhaler Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Senshio.
See on ravimi Senshio Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Sevelamer carbonate Zentiva.
See on ravimi Sevelamer carbonate Zentiva Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for SevoFlo.
See on ravimi SevoFlo Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Sevohale.
See on ravimi Sevohale Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Simponi.
See on ravimi Simponi Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Soliris.
See on ravimi Soliris Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Somavert.
See on ravimi Somavert Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Sovaldi.
See on ravimi Sovaldi Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Stayveer.
See on ravimi Stayveer Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Strensiq.
See on ravimi Strensiq Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Sylvant.
See on ravimi Sylvant Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Tafinlar.
See on ravimi Tafinlar Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Tagrisso.
See on ravimi Tagrisso Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Tamiflu.
See on ravimi Tamiflu Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Tasigna.
See on ravimi Tasigna Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Taxespira.
Tervishoiutöötajatel palutakse teavitada kõigist võimalikest kõrvaltoimetest riikliku teavitamissüsteemi, mis on loetletud V lisas, kaudu.
This is a summary of the European public assessment report (EPAR) for Thalidomide Celgene.
See on ravimi Thalidomide Celgene Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Torisel.
See on ravimi Torisel Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Tovanor Breezhaler.
See on ravimi Tovanor Breezhaler Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Tracleer.
See on ravimi Tracleer Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Translarna.
See on ravimi Translarna Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Truvada.
See on ravimi Truvada Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European Public Assessment Report (EPAR) for Vectibix.
See on ravimi Vectibix Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Viekirax.
See on ravimi Viekirax Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Volibris.
See on ravimi Volibris Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Voriconazole Hospira.
See on ravimi Voriconazole Hospira Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Votubia.
See on ravimi Votubia Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Xagrid.
See on ravimi Xagrid Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Xarelto.
See on ravimi Xarelto Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Xeloda.
See on ravimi Xeloda Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Xgeva.
See on ravimi Xgeva Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Xigduo.
See on ravimi Xigduo Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Xofigo.
See on ravimi Xofigo Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Xtandi.
See on ravimi Xtandi Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Xultophy.
See on ravimi Xultophy Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Yellox.
Käesolev dokument on ravimi Yellox Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Yervoy.
See on ravimi Yervoy Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for ZACTRAN.
See on ravimi ZACTRAN Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Zebinix.
See on ravimi Zebinix Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Zelboraf.
See on ravimi Zelboraf Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Zerbaxa.
See on ravimi Zerbaxa Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Zinforo.
See on ravimi Zinforo Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Zoledronic Acid Accord.
See on ravimi Zoledronic Acid Accord Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Zydelig.
See on ravimi Zydelig Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European public assessment report (EPAR) for Zykadia.
See on ravimi Zykadia Euroopa avaliku hindamisaruande kokkuvõte.
This is a summary of the European Public Assessment Report (EPAR).
See on veterinaarravimi Advocate Euroopa avaliku hindamisaruande kokkuvõte.
This is a total daily dose of 60 mg.
Seega on ööpäevane annus kokku 60 mg.
This is a type of cytokine (an immunosuppressive agent) that is used to treat rheumatoid arthritis.
See on tsütokiin (immunosupressant), mida kasutatakse reumatoidartriidi raviks.
This is a type of cytokine (an immunosuppressive agent) that is used to treat:
See on tsütokiin (immunosupressant), mida kasutatakse järgmiste haiguste raviks: reumatoidartriit (RA);
This is a type of epilepsy where too much electrical activity in one side of the brain causes symptoms such as sudden, jerky movements of one part of the body, distorted hearing, sense of smell, or vision, numbness or a sudden sense of fear.
See on epilepsia vorm, kus aju ühe poolkera elektriline liigtalitlus tekitab selliseid sümptomeid nagu ühe kehapoole järsud tõmblused, kuulmis-, haistmis- või nägemishäired, tuimus või äkiline hirmutunne.
This is a way of measuring the change in exercise capacity (the ability to carry out physical activity).
See on üks koormustaluvuse muutuse hindamise viise.
This is a ‘primary bile acid’, which is a main component of the bile (a fluid produced by the liver that helps to digest fats).
Koolhape on esmane sapphape, mis on sapi (maksa eritatav vedelik, mis aitab rasvu seedida) põhikomponent.
This is acceptable because of the current political and epidemiological situation in Europe with regard to avian influenza.
See on Euroopa praeguses linnugripiga seotud poliitilises ja epidemioloogilises olukorras vastuvõetav.
This is achieved by snapping it off.
Selleks tuleb süstlikork ära murda.
This is achieved by thoroughly mixing Aivlosin into approximately 200–500 g of feed and then thoroughly mixing this pre-mixture into the remainder of the daily ration.
Selleks lisatakse Aivlosin hoolikalt segades ligikaudu 200–500 g söödasse ning segatakse see eelsegu põhjalikult ülejäänud päevase söödakoguse sisse.
This is achieved by thoroughly mixing the required amount of Econor oral powder into the daily ration for each individual pig.
Nõutav kogus Econor’i suukaudset pulbrit tuleb hoolikalt iga üksiku sea päevase sööda sisse segada.
This is already included in the Company Core Safety Information as an undesirable effect and as a symptom of overdose (“drowsiness”).
See on juba esitatud ettevõtte ohutusalases põhiteabes kõrvaltoimena ja üleannustamise sümptomina („uimasus”).
This is an antibiotic used to treat infections such as tuberculosis.
Seda antibiootikumi kasutatakse infektsioonide, näiteks tuberkuloosi raviks;
This is an antiviral medicine that blocks an enzyme called integrase that is needed by the HIV virus to make new copies of itself in the body.
See on viiruseravim, mis blokeerib ensüümi nimega integraas, mida HIV vajab inimese organismis paljunemiseks (iseenda koopiate tegemiseks).
This is an inherited condition in which numerous fluid-filled cysts develop in the kidneys, which eventually affect kidney function and can cause the kidneys to fail.
See on pärilik haigus, mis põhjustab neerudes vedelikuga täitunud tsüstide teket, mis kahjustavad neerutalitlust ja võivad põhjustada neerupuudulikkust.
This is an open-label study of alipogene tiparvovec at a fixed dose of 1x1012 gc/ kg body weight administered by a single series of intramuscular injections.
See on avatud alipogeentiparvoveki fikseeritud annuse (1 × 1012 gk/kg kehakaalu kohta, mida masnustatakse intramuskulaarse süstina ühekordse seeriana) uuring.
This is as long as medical treatment is available straight away, in case you have an allergic reaction
Seda juhul, kui käepärast on kohene meditsiiniline abi allergilise reaktsiooni raviks.
This is based on Pharmacokinetic data only (see section 5.2. Pharmacokinetic Properties).
See põhineb ainult farmakokineetilistel andmetel (vt lõik 5.2 Farmakokineetilised omadused).
This is based on the results from a clinical trial in which a combined dTap-IPV vaccine was administered concomitantly with the first dose of Gardasil. (see section 4.8).
See baseerub kliinilise uuringu tulemustel, millega kombineeritud DTPa-IPV vaktsiini manustati samaaegselt Gardasil’i esimese annusega (vt lõik 4.8).
This is based on the results from a clinical trial in which a combined dTap-IPV vaccine was administered concomitantly with the first dose of Silgard (see section 4.8).
See baseerub kliinilise uuringu tulemustel, millega kombineeritud DTPa-IPV vaktsiini manustati samaaegselt Silgard’i esimese annusega (vt lõik 4.8).
This is based on your size (height and weight) and if you have a recurrent tumour and have had chemotherapy treatment in the past.
Seda tehakse juhindudes teie pikkusest ja kehakaalust ning sellest, kas teil on taastekkinud kasvaja ja kas te olete varem saanud keemiaravi.
This is based upon clinical data in children > 1 year of age and adults showing that a prophylaxis dose equivalent to half the daily treatment dose is clinically efficacious for the prevention of influenza (see Section 5.2 for exposure simulation).
See põhineb üle 1-aastastelt lastelt ja täiskasvanutelt saadud kliinilistel andmetel, mis näitavad, et poolele ööpäevasele raviannusele vastav profülaktiline annus on gripi ennetamisel kliiniliselt efektiivne (ekspositsiooni simuleerimise kohta vt lõik 5.2).
This is based upon pharmacokinetic and safety data indicating that this dose in infants 0 - 12 months provides plasma concentrations of the pro-drug and active metabolite that are anticipated to be clinically efficacious with a safety profile comparable to that seen in older children and adults (see section 5.2).
See põhineb farmakokineetilistel ja ohutusandmetel, mis näitavad, et antud annuse kasutamisel 0...12 kuu vanustel väikelastel saavutatakse selline eelravimi ja aktiivse metaboliidi plasmakontsentratsioon, mis on eeldatavasti kliiniliselt efektiivne ja mille ohutusprofiil on võrreldav vanematel lastel ja täiskasvanutel täheldatuga (vt lõik 5.2).
This is based upon pharmacokinetic and safety data indicating that this dose in infants 0 - 12 months provides plasma concentrations of the pro-drug and active metabolite that are anticipated to be clinically efficacious with a safety profile comparable to that seen in older children and adults (see section 5.2).
See põhineb farmakokineetilistel ja ohutusandmetel, mis näitavad, et antud annuse kasutamisel 0…12 kuu vanustel väikelastel saavutatakse selline eelravimi ja aktiivse metaboliidi plasmakontsentratsioon, mis on eeldatavasti kliiniliselt efektiivne ja mille ohutusprofiil on võrreldav vanematel lastel ja täiskasvanutel täheldatuga (vt lõik 5.2).
This is because aminoglycosides and Bondronat can both lower the amount of calcium in your blood
See on vajalik sellepärast, et aminoglükosiidid ja Bondronat võivad mõlemad langetada vere kaltsiumisisaldust.
This is because aminoglycosides and Iasibon can both lower the amount of calcium in your blood
See on vajalik sellepärast, et aminoglükosiidid ja Iasibon võivad mõlemad langetada vere kaltsiumisisaldust.
This is because Brilique can affect the way some medicines work and some medicines can have an effect on Brilique.
Need võivad mõjutada Brilique’i toimet ning Brilique võib mõjutada teiste ravimite toimet.
This is because Caprelsa can affect the way some medicines work and some medicines can have an effect on Caprelsa.
See on vajalik seeõttu, et Caprelsa võib mõjustada mõnede teiste ravimite toimimisviisi ja mõned ravimid võivad avaldada toimet Caprelsale.
This is because Caprelsa may harm an unborn child.
See on vajalik seetõttu, et Caprelsa võib kahjustada loodet.